By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Being laid off is bad enough. When companies mishandle the layoff process, it can make the situation even worse. Four ...

J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...